Trial Profile
Comparison of Anti-vascular Endothelial Growth Factors Agents in the Treatment of Macular Edema Following Retinal Vein Occlusion
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2017
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Ranibizumab (Primary)
- Indications Retinal oedema; Retinal vein occlusion
- Focus Therapeutic Use
- Acronyms CRAVE
- 18 May 2016 New trial record